MY139643A - Vinflunine pharmaceutical composition for parenteral administration, preparation process and use thereof. - Google Patents

Vinflunine pharmaceutical composition for parenteral administration, preparation process and use thereof.

Info

Publication number
MY139643A
MY139643A MYPI20045331A MYPI20045331A MY139643A MY 139643 A MY139643 A MY 139643A MY PI20045331 A MYPI20045331 A MY PI20045331A MY PI20045331 A MYPI20045331 A MY PI20045331A MY 139643 A MY139643 A MY 139643A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical composition
parenteral administration
preparation process
vinflunine
vinflunine pharmaceutical
Prior art date
Application number
MYPI20045331A
Other languages
English (en)
Inventor
Leverd Elie
Bougaret Joel
Ibarra Marie-Dominique
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34630533&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY139643(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MY139643A publication Critical patent/MY139643A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20045331A 2003-12-23 2004-12-23 Vinflunine pharmaceutical composition for parenteral administration, preparation process and use thereof. MY139643A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0315312A FR2863891B1 (fr) 2003-12-23 2003-12-23 Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation

Publications (1)

Publication Number Publication Date
MY139643A true MY139643A (en) 2009-10-30

Family

ID=34630533

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20045331A MY139643A (en) 2003-12-23 2004-12-23 Vinflunine pharmaceutical composition for parenteral administration, preparation process and use thereof.

Country Status (35)

Country Link
US (1) US20070155768A1 (zh)
EP (1) EP1696913B1 (zh)
JP (2) JP5226220B2 (zh)
KR (1) KR101166347B1 (zh)
CN (2) CN1897940A (zh)
AR (1) AR047346A1 (zh)
AT (1) ATE424201T1 (zh)
AU (1) AU2004314154B2 (zh)
BR (1) BRPI0418005B8 (zh)
CA (1) CA2551493C (zh)
CR (1) CR8473A (zh)
CY (1) CY1109120T1 (zh)
DE (1) DE602004019809D1 (zh)
DK (1) DK1696913T3 (zh)
EC (1) ECSP066663A (zh)
ES (1) ES2323374T3 (zh)
FR (1) FR2863891B1 (zh)
HK (1) HK1089105A1 (zh)
IL (1) IL176404A (zh)
MA (1) MA28237A1 (zh)
MX (1) MXPA06007208A (zh)
MY (1) MY139643A (zh)
NI (1) NI200600146A (zh)
NO (1) NO336427B1 (zh)
NZ (1) NZ548028A (zh)
OA (1) OA13348A (zh)
PL (1) PL1696913T3 (zh)
PT (1) PT1696913E (zh)
RU (1) RU2362557C2 (zh)
SI (1) SI1696913T1 (zh)
TN (1) TNSN06197A1 (zh)
TW (1) TWI334352B (zh)
UA (1) UA83888C2 (zh)
WO (1) WO2005070425A1 (zh)
ZA (1) ZA200605201B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110015221A1 (en) * 2003-12-23 2011-01-20 Pierre Fabre Medicament Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
FR2910812B1 (fr) * 2006-12-29 2009-03-20 Pierre Fabre Medicament Sa Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante
FR2912406B1 (fr) * 2007-02-13 2009-05-08 Pierre Fabre Medicament Sa Sels cristalins anhydres de vinflunine, procede de preparation et utilisation en tant que medicament et moyen de purification de la vinflunine.
EP1997534A1 (en) * 2007-05-31 2008-12-03 Pierre Fabre Medicament Cancer treatment combination therapy comprising vinflunine and trastuzumab
CN101129374B (zh) * 2007-06-26 2010-09-08 齐鲁制药有限公司 长春氟宁药物组合物及其制备方法与应用
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
FR2918566B1 (fr) * 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
CN101607968A (zh) * 2008-06-17 2009-12-23 江苏豪森药业股份有限公司 长春氟宁盐、其制备方法及其药物组合物
US20140018398A1 (en) * 2011-03-29 2014-01-16 Sanofi Otamixaban formulations with improved stability
WO2017021981A1 (en) * 2015-08-01 2017-02-09 Sun Pharmaceutical Industries Ltd. Dosage form of vinca alkaloid drug
WO2018007554A1 (en) * 2016-07-06 2018-01-11 Pierre Fabre Medicament Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307100A (en) * 1978-08-24 1981-12-22 Agence Nationale De Valorisation De La Recherche (Anvar) Nor bis-indole compounds usable as medicaments
US4619935A (en) * 1983-03-17 1986-10-28 Eli Lilly And Company Stable oncolytic formulations
HU195513B (en) * 1984-10-16 1988-05-30 Richter Gedeon Vegyeszet Process for producing stable solutions of alkaloides with bis-indole skeleton
FR2597750B1 (fr) * 1986-04-25 1989-06-02 Pf Medicament Solution aqueuse stable de sulfate de vincristine
IL83086A (en) * 1987-07-06 1991-03-10 Teva Pharma Stable,injectable solutions of vincristine salts
US4923876A (en) * 1988-04-18 1990-05-08 Cetus Corporation Vinca alkaloid pharmaceutical compositions
CA2001643A1 (en) * 1988-12-23 1990-06-23 Richard L. Wolgemuth Preservative-free multi-dose vincristine solution
HU204995B (en) * 1989-11-07 1992-03-30 Richter Gedeon Vegyeszet Process for producing pharmaceutical composition comprising alkaloid with bis-indole skeleton, with antitumour activity and suitable fr parenteral purposes
JPH06100452A (ja) * 1993-04-06 1994-04-12 Asta Medica Ag イホスファミド用の製薬学的容器
FR2707988B1 (fr) * 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
DE19706255C2 (de) * 1997-02-18 2000-11-30 Schott Glas Sterilisierbarer Glasbehälter für medizinische Zwecke, insbesondere zur Aufbewahrung pharmazeutischer oder diagnostischer Produkte
FR2761990B1 (fr) * 1997-04-10 1999-06-25 Pf Medicament Derives halogenes antimitotiques d'alcaloides de vinca
JP3642492B1 (ja) * 2003-10-31 2005-04-27 小野薬品工業株式会社 オザグレルナトリウム含有水溶液を充填してなる注射用容器
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation

Also Published As

Publication number Publication date
CA2551493C (fr) 2012-12-04
IL176404A0 (en) 2006-10-05
OA13348A (fr) 2007-04-13
PT1696913E (pt) 2009-06-05
US20070155768A1 (en) 2007-07-05
FR2863891B1 (fr) 2006-03-24
UA83888C2 (ru) 2008-08-26
TNSN06197A1 (fr) 2007-11-15
DK1696913T3 (da) 2009-06-29
MXPA06007208A (es) 2006-08-18
KR20060124624A (ko) 2006-12-05
EP1696913A1 (fr) 2006-09-06
RU2362557C2 (ru) 2009-07-27
AU2004314154B2 (en) 2011-03-24
TW200531717A (en) 2005-10-01
JP2012102120A (ja) 2012-05-31
FR2863891A1 (fr) 2005-06-24
ECSP066663A (es) 2006-10-25
NO336427B1 (no) 2015-08-17
ATE424201T1 (de) 2009-03-15
NI200600146A (es) 2006-12-12
NO20063277L (no) 2006-07-14
MA28237A1 (fr) 2006-10-02
JP5710462B2 (ja) 2015-04-30
RU2006126708A (ru) 2008-01-27
KR101166347B1 (ko) 2012-07-18
ES2323374T3 (es) 2009-07-14
JP2007515461A (ja) 2007-06-14
CA2551493A1 (fr) 2005-08-04
PL1696913T3 (pl) 2009-08-31
BRPI0418005B8 (pt) 2021-05-25
AR047346A1 (es) 2006-01-18
EP1696913B1 (fr) 2009-03-04
WO2005070425A1 (fr) 2005-08-04
IL176404A (en) 2010-11-30
JP5226220B2 (ja) 2013-07-03
BRPI0418005A (pt) 2007-04-17
BRPI0418005B1 (pt) 2019-11-26
CY1109120T1 (el) 2014-07-02
TWI334352B (en) 2010-12-11
HK1089105A1 (en) 2006-11-24
CN101695474A (zh) 2010-04-21
ZA200605201B (en) 2007-09-26
SI1696913T1 (sl) 2009-08-31
AU2004314154A1 (en) 2005-08-04
NZ548028A (en) 2010-01-29
CR8473A (es) 2006-11-24
DE602004019809D1 (de) 2009-04-16
CN1897940A (zh) 2007-01-17

Similar Documents

Publication Publication Date Title
NO20063277L (no) Farmasoytisk sammensetning av vinflunin som er ment for parenteral administrering, fremstillingsmate og anvendelse derav
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
IL163817A (en) Derivatives of –4,2 Diaminopyrimidine, Process for Preparation, Pharmaceutical Preparations Containing Them, and Use in Preparation of Breast Cancer Drugs
HK1057752A1 (en) N-phenyl-2-pyrimidine-amine derivatives
UA86977C2 (ru) Производные гидантоина для лечения обструктивных болезней дыхательных путей
YU29502A (sh) Proces dobijanja 4"-supstituisanog 9-dezokso-9a-aza-9a derivata homoeritromicina a
MY133732A (en) Sulfonylcarboxamide derivatives, process for their preparation and their use as medicines
GEP20063895B (en) Platinum derivative pharmaceutical formulations
RS41104A (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
TW200510392A (en) Chemical compounds
GEP20053492B (en) 5-Chloro-3-(4-Methanesulfonylphenyl)-6'-Methyl- [2,3']Bipyridinyl in Pure Crystalline Form and Process for Production Thereof
TW200505452A (en) Chemical compounds
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
HK1090354A1 (en) Novel dibenzo [b,f]oxepine-10-carboxamides and pharmaceutical uses thereof
TW200745155A (en) Preparation of pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl)betulinic acid
PL357999A1 (en) Lhrh-antagonists, production and use thereof as medicament
TW200504051A (en) Novel acridine derivatives and their use as medicaments
HRP20020238A2 (en) 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use
UA88884C2 (ru) Набор для приготовления фармацевтических композиций цис-оксоплатина, фармацевтическая композиция и ее применение при лечении рака
NO20055998L (no) Diarylmetylidenpiperidinderivater, preparater derav og anvendelse derav
WO2005049483A3 (de) Reaktive chlorverbindungen, deren derivate, anionen und salze sowie verfahren zu deren herstellung und verwendung
UA74406C2 (uk) Полісахаридна сполука з імуностимулювальною активністю, спосіб її одержання, застосування та фармацевтичний препарат на її основі
MXPA05003633A (es) 2"-oxo-voruscharina y derivados de la misma.
YU41003A (sh) Polisaharidno jedinjenje koje poseduje imuno stimulativno dejstvo
TH81540A (zh)